Vascular Disease, Alzheimer's Disease, and Mild Cognitive Impairment
David J. Libon, Melissa Lamar, Rodney A. Swenson, Kenneth M. Heilman· ISBN 9780190634230
Special offer terms
Zookal Study Premium
Subscribe & save
By selecting the 'Susbcribe & Save' option you are enrolling in an auto-renewing subscription of Zookal Study Premium. Cancel at anytime.
Auto-Renewal
Your Zookal Study Premium subscription will be renewed each month until you cancel. You consent to Zookal automatically charging your payment method on file $19.99 each month after 1st month free period until you cancel.
How to Cancel
You can cancel your subscription anytime by visiting Manage account page, clicking "Manage subscription" and completing the steps to cancel. Cancellations take effect at the end of the 1st month free period (if applicable) or at the end of the current billing cycle in which your request to cancel was received. Subscription fees are not refundable.
Zookal Study Premium Monthly Subscription Includes:
Ability to post up to ten (10) questions per month.
20% off your textbooks order and free standard shipping whenever you shop online at
textbooks.zookal.com.au
Unused monthly subscription benefits have no cash value, are not transferable, and expire at the end of each month. This means that subscription benefits do not roll over to or accumulate for use in subsequent months.
Payment Methods
Afterpay and Zip Pay will not be available for purchases with Zookal Study Premium subscription added to bag.
$1.00 preauthorisation
You may see a $1.00 preauthorisation by your bank which will disappear from your statement in a few business days..
Email communications
By adding Zookal Study Premium, you agree to receive email communications from Zookal.
Alzheimer's disease (AD) and vascular dementia (VaD) are commonly viewed as the first and second most common types of dementia, respectively. The traditional paradigm has been to view and treat each illness as a separate entity with a separate pathophysiology. However, clinical and pathological studies suggest that the boundary separating AD and VaD, as well as their mild cognitive impairment (MCI) analogs, is not well defined. Thus, there is increased interest in
viewing these diseases along a spectrum because of the significant overlap in the characterization and diagnosis of AD, VaD, and MCI. The focus of this edited volume is to examine how AD and VaD, as
well as their MCI analogs, are best viewed as a heterogeneous, intersecting, if not a continuous disease state rather than separate, distinct entities. This book examines this approach by providing empirically based evidence, reviews of the literature, and chapters by key leaders in the field and will be of interest to clinical neuropsychologists and anyone studying or treating dementia in its many forms.